Hervé Hoppenot (Incyte Corporation (Nasdaq: INCY))

Hoppenot, Hervé (Incyte 201401– CEO before Novartis President Oncology)

	Organisation	Incyte Corporation (Nasdaq: INCY)
	Group	Incyte Corporation (Group)
	Former/major organisation	Novartis Oncology (business unit, since 7/16)
	Group	Novartis (Group)
	Product	small-molecule cancer drug
	Product 2	oncology

Record changed: 2024-03-11

Picture Berlin Partner Top News Robotics Network Berlin-Brandenburg 650x200px

More documents for Hervé Hoppenot

[1] Pierre Fabre Laboratories. (1/10/24). "Press Release: Hervé Hoppenot, Incyte CEO, Is Appointed on the Board of Pierre Fabre Laboratories". Castres....
[2] MorphoSys AG. (8/26/21). "Press Release: MorphoSys and Incyte Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma". Plan...
[3] MorphoSys AG. (11/11/20). "Press Release: Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab". Monrovia, CA, Planegg & Wilmington, DE....
[4] MorphoSys AG. (8/1/20). "Press Release: FDA Approves Monjuvi (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)". Planegg & Wilmington, DE....
[5] MorphoSys AG. (1/13/20). "Press Release: MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab". Planegg & Wilmington, DE....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]